Hepatitis C is a viral infection of the liver caused by the hepatitis C virus (HCV) and spread through blood-to-blood exposure. The majority of people exposed to HCV develop chronic infection, which can cause cirrhosis resulting in liver failure, liver cancer, or even the need for liver transplantation.
Global Liver Institute
GLOBAL LIVER INSTITUTE
Can Blood Tests Help Predict Liver Transplant Outcomes? – Pediatric & Rare Liver Diseases News
As we conclude this year, the Pediatric and Rare Liver Diseases team is reflecting on the incredible progress made by our council and patient organizations in 2024.
Congress debates appropriations and other end-of-year legislation. Biden administration issues more rulemakings. Agencies prepare for new leadership. – Liver Health Policy Update
Members of Congress have returned to Washington, DC. It is unclear if many healthcare priorities will make it to final passage this year. The incoming administration has submitted names for its new Cabinet and to lead key agencies.
The Most Common Chronic Liver Disease in the World – Fatty Liver Disease News
Last month, the GLI team proudly attended AASLD’s The Liver Meeting™, starting with our 10th anniversary celebration, which brought together patient advocates, industry leaders, and liver community members to celebrate a decade of impactful work.
Global Liver Institute’s Statement on Centers for Medicare & Medicaid Services Obesity Coverage Proposed Rule
Global Liver Institute is thrilled to share that the Centers for Medicare & Medicaid Services (CMS) has proposed to align coverage policy to reflect the understanding that obesity is a chronic disease.
Healthy Holidays! Gut Friendly Tips and Liver Health Innovations – Liver Cancer News
Welcome back to this special holiday edition of Liver Cancer News! As the festive season begins, read on to discover articles on liver cancer health, the latest management tools, and recent innovations.
Global Liver Institute Acknowledges FDA Request for Further Studies as Obeticholic Acid Remains Available for PBC Patients
Global Liver Institute (GLI) acknowledges the U.S. Food and Drug Administration’s (FDA) decision today to issue a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) of obeticholic acid (OCA, OCALIVA®) for primary biliary cholangitis (PBC).
After elections, a lame-duck Congress will need to pass appropriations bills and hopefully “clear the decks” by passing long-awaited health reforms – Liver Health Policy Update
Members of Congress will return to Washington, DC, after the elections. Hopes remain for a productive November legislative session where some legislative priorities may finally make it to final passage.
Uniting for Equity in Liver Cancer Care – Liver Cancer News
In October, Global Liver Institute led its annual #OctoberIs4Livers campaign, focused on health equity and raising awareness about liver cancer.
Innovation Sparks New Ideas at NORD’s Breakthrough Summit – Pediatric & Rare Liver Diseases News
Kristin Hatcher spent three days in Washington, D.C., at the NORD Breakthrough Summit to discuss equitable access to innovation.
Screening for MASLD is Cost-Effective for Patients – Fatty Liver Disease News
In this issue, we explore recent findings that highlight the need for dietary changes, including the link between ultra-processed foods and metabolic disorders in children with obesity, as well as the benefits of increasing plain water intake can reduce mortality risk.
Terri’s Story
When my doctor told me that I had fatty liver disease in 2015, the communication was that it was no big deal. In 2016, I was diagnosed with lupus then pancreatitis. Eventually, the pain, discomfort and fatigue from gallstones led me to an elective gallbladder surgery in 2017. During the surgery, my well-meaning surgeon found my liver to be nodular and decided to biopsy three separate spots while in the process of removing my gallbladder. What my surgeon did not know is how that biopsy would trigger a series of complications for my fragile liver.